Warning: include_once(../article_type.php): failed to open stream: No such file or directory in /home/suxhorbncfos/public_html/jocct/JOCCT.MS.ID.555813.php on line 118
Warning: include_once(): Failed opening '../article_type.php' for inclusion (include_path='.:/opt/alt/php56/usr/share/pear:/opt/alt/php56/usr/share/php') in /home/suxhorbncfos/public_html/jocct/JOCCT.MS.ID.555813.php on line 118
Who is the Right Patient for Trans-Catheter
Mitral Edge-to-Edge Repair?
Ching Wei Lee1,2,3,4 and Shih Hsien Sung1,3*
1 Department of Medicine, Taipei Veterans General Hospital, Taiwan
2 Department of Medical Affairs and Planning, Taipei Veterans General Hospital, Taiwan
3 Cardiovascular Research Center, National Yang-Ming University, Taiwan
4 Institute of Health Policy and Management, National Taiwan University, Taiwan
Submission:May 25, 2018;Published: July 13, 2018
*Corresponding author: Shih Hsien Sung, Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan,
Tel:(866)-2-28712121 ; Fax: (886)-2-28717431; Email: email@example.com
How to cite this article: Ching W L, Shih H S. Who is the Right Patient for Trans-Catheter Mitral Edge-to-Edge Repair?. J Cardiol & Cardiovasc Ther. 2018;
11(3): 555813. DOI: 10.19080/JOCCT.2018.11.555813
Compare to surgical mitral valve intervention, trans-catheter mitral edge-to-edge repair show better procedural safety in patients with severe mitral regurgitation (MR). On the other hand, there is still a concern that more recurrent MR is observed in surgical eligible patients treated with Mitra Clip. As a result, trans-catheter mitral edge-to-edge repair is reserved for subjects with high or prohibitive surgical risk. In the real-world practice, majority of subjects with advanced age, severely depressed left ventricular systolic function, or in critical conditions are put in medical treatment alone rather than either surgical or trans-catheter mitral intervention. To improve the utilization of Mitra Clip in suitable patients, we will go through current evidence to identify the procedural safety and efficacy for trans-catheter mitral repair.
More than 10% of the subjects, aged ≥75 years have moderate to severe mitral regurgitation (MR) . MR is a debilitating, progressive and life-threatening disease, which occurs when the leaflets of the mitral valve do not close completely, causing blood to flow backwards into the left atrium of the heart and the lungs during the cardiac cycles. Patients with symptomatic severe MR, if left untreated, would experience progressive heart failure, and the 5-year mortality rate could be as high as 50% . The etiology of MR is classified as degenerative MR (pro-lapsing leaflets or rupture chordae) and functional MR (consequence of annulus dilatation or abnormal left ventricular function) . The burden of MR is substantial along with the prolonging of life expectancy, the trend of deaths related with valvular heart disease upstroke significantly in the past three decades . Of the 39 billion in annual heart failure costs in the US, approximately 60% is due to heart failure hospitalization, many of which are associated with MR .
The current therapeutic option for clinical significant MR is open-heart surgery to repair or replace the mitral valve. However,
it is mandatory to use cardiopulmonary bypass in open-heart surgery, which could be a challenge to patient with advanced age or poor left ventricular systolic function. In fact, patients who are deemed too high risk to undergo mitral valve surgery have no other treatment option except ineffective medical therapy alone. More than 85% of the octogenarians and patients with poor left ventricular systolic function (LVEF< 30%) who are declined to receive open-heart surgery because of high or prohibitive surgical risk . The expected number of underutilization in mitral valve surgery could be higher in Asians due to culture differences between east and west. There is a clinical unmet need in treating severe MR properly.
After the safety and efficacy been proven in the randomized controlled trial, the Endovascular Valve Edge-to-Edge Repair Study (EVEREST II) [7,8], Mitra Clip (Abbott Vascular, Menlo Park, CA, USA) received FDA approval on October 24, 2013 and is indicated for the percutaneous reduction of significant symptomatic MR in patients who have been determined to be prohibitive risk for mitral valve surgery by a heart team. Over the last 10 years, multiple clinical studies have been performed to establish a reasonable safety and long-term impact on improvement in quality of life for this procedure. On the other hand, there is still a concern that more recurrent MR is observed in patients treated
with Mitra clip compared to surgical mitral valve intervention. As
a result, trans-catheter mitral edge-to-edge repair is reserved for
subjects with high or prohibitive surgical risk .
Murashita et al.  demonstrated acceptable procedure
safety (7.3% in-hospital mortality) and long-term survival (81%
at 5 years) in subjects older than 75 years who underwent
surgical mitral valve repair. However, limited case number (N=55)
and single center design are the main limitations of this research.
The mean age of the elderly patients is 77 years old, which is also
not representative to octogenarians . By systemic review and
meta-analysis, Andalib et al.  showed surgical treatment of MR
in octogenarians is associated with high preoperative mortality
(7-13% post-operative mortality) and poor long-term survival
(67% and 29% survival rate at 1 and 5 years) with an uncertain
benefit on quality of life. On the other hand, Buzzatti et al. 
found 25 octogenarians who underwent Mitra Clip, despite being
older, more symptomatic and affected by more co morbidities
showed significantly reduced postoperative complications
(P< 0.05) as compared to surgical groups (N=35). From GRASP
(Getting Reduction of Mitral Insufficiency by Percutaneous Clip
Implantation) registry, Mitra Clip was shown to be safe and
effective in most patients, with similar hospital length of stay,
one-year clinical outcomes and re-hospitalization rates in either
elderly or younger patients .
For patients with severe degenerative MR and LVEF less than
30%, optimal medical treatment is the frontline therapy suggested
by the current guideline because of high risk for peri-operative
mortality and morbidities. From the Euro SCORE II risk prediction
model, subjects with LVEF< 30% will carry 40% increased risk in
open-heart surgery [14,15]. Left ventricular systolic dysfunction,
a traditional risk predictor in surgical prediction model is not
associated with worse outcome after trans-catheter mitral valve
repair. Barth et al.  demonstrated fair procedural safety and
even similar improvements in exercise capacity in both patients
with advanced LV dysfunction (LVEF<20%) or not .
Emergent open-heart surgery to rescue patients under
mechanical hemodynamic support is really challenging, especially
when patients carry multiple co-morbidities. Several case reports
have demonstrated Mitra Clip can be used to rescue patients under
extracorporeal membrane oxygenation (ECMO) support  and
even with acute myocardial infarction (AMI) and papillary muscle
rupture [19,20]. Adamo et al.  showed critically ill patients
with acute ischemic MR can benefit from Mitra Clip procedure
acutely with favorable long-term follow-up results. In our center,
we have treated 1 patient under ECMO support and 1 patient with
acute papillary muscle rupture after AMI. Both patients recovery
well and can discharge to home after emergent procedure. The
value of trans-catheter intervention in critical illness is safe and
effective procedure per se.
To date, the EVEREST criteria have been acknowledged as
the basic of an anatomical selection process. In EVEREST study,
the anatomical eligible for Mitra Clip procedure comprised that
a primary regurgitation originating from central A2/P2 region,
cooptation length greater than 2mm and cooptation depth less
than 11mm in FMR, and flail gap less than 10mm and width less
than 15mm in DMR . However, there were only limited cases to
fulfill the strict echocardiography criteria for Mitra Clip procedure.
In fact, Attizzani et al.  have shown with reasonable expanded
echocardiography features, the safety and efficacy are comparable
to EVEREST eligible patients. However, patients with mitral cleft,
rheumatic mitral stenos is, active endocarditic, or inadequate
length of posterior mitral leaflet (< 7mm) are discouraged to
receive Mitra Clip procedure.
Trans-catheter edge-to-edge mitral valve repairs are safe
and effective in patients with severe MR who carry high or
prohibitive surgical risk. Mitra Clip is an alternative or even the
only solution to rescue severe MR patients with advanced age,
poor left ventricular systolic function, or critical conditions under